High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4+ and CD8+ neoantigen-specific T cells to promote antitumor immunity.

Rosmely HernandezKathryn M LaPorteSunnie HsiungAlicia Santos SavioThomas R Malek

Published in: Journal for immunotherapy of cancer (2022)

These results indicate that neoantigen-based vaccines are optimized by potentiating IL-2R signaling in CD4+ and CD8+ neoantigen-reactive T cells by using high-dose mIL-2/CD25, leading to more effective tumor clearance.

Keyphrases

high dose
nk cells
stem cell transplantation
mass spectrometry
endothelial cells
diabetic rats
solid phase extraction